Does the media favor CRDF or EVAX?

In the previous week, Cardiff Oncology and Cardiff Oncology both had 3 articles in the media. Cardiff Oncology's average media sentiment score of 0.91 beat Evaxion A/S's score of 0.89 indicating that Cardiff Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiff Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EVAX or DTSQ?

Evaxion A/S presently has a consensus target price of $11.00, indicating a potential upside of 236.39%. Given Evaxion A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Evaxion A/S is more favorable than DT Cloud Star Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 DT Cloud Star Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, EVAX or DTSQ?

DT Cloud Star Acquisition has lower revenue, but higher earnings than Evaxion A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evaxion A/S $7.53M 3.92 -$7.71M -$1.21 N/A DT Cloud Star Acquisition N/A N/A N/A N/A N/A

Is EVAX or DTSQ more profitable?

DT Cloud Star Acquisition's return on equity of 0.00% beat Evaxion A/S's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% DT Cloud Star Acquisition N/A N/A N/A

Do analysts prefer AADI or EVAX?

Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 236.39%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is ONCY or EVAX more profitable?

Evaxion A/S's return on equity of -61.43% beat Oncolytics Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Oncolytics Biotech N/A -2,185.97% -442.99% Evaxion A/S N/A -61.43% -34.23%

Does the media prefer ONCY or EVAX?

In the previous week, Oncolytics Biotech had 4 more articles in the media than Evaxion A/S. MarketBeat recorded 7 mentions for Oncolytics Biotech and 3 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.89 beat Oncolytics Biotech's score of 0.54 indicating that Evaxion A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncolytics Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EVAX or CTOR?

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 236.39%. Given Evaxion A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Evaxion A/S is more favorable than Citius Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Citius Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EVAX or CTOR more profitable?

Evaxion A/S's return on equity of -61.43% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Evaxion A/S N/A -61.43% -34.23% Citius Oncology N/A -102.98% -43.49%

Does the media refer more to EVAX or CTOR?

In the previous week, Evaxion A/S and Evaxion A/S both had 3 articles in the media. Citius Oncology's average media sentiment score of 1.23 beat Evaxion A/S's score of 0.89 indicating that Citius Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Citius Oncology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Evaxion A/S (EVAX) Competitors

$3.27 +0.03 (+0.93%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$3.32 +0.05 (+1.44%)

As of 09/29/2026 07:55 PM Eastern

Compare

EVAX vs. CRDF, DTSQ, AADI, ONCY, and CTOR

Should you buy Evaxion A/S stock or one of its competitors? Evaxion A/S's main competitors and comparable companies include Cardiff Oncology (CRDF), DT Cloud Star Acquisition (DTSQ), Aadi Bioscience (AADI), Oncolytics Biotech (ONCY), and Citius Oncology (CTOR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Evaxion A/S compare to Cardiff Oncology?

Cardiff Oncology (NASDAQ:CRDF) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Evaxion A/S has a net margin of 0.00% compared to Cardiff Oncology's net margin of -7,885.43%. Evaxion A/S's return on equity of -61.43% beat Cardiff Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-7,885.43%	-103.10%	-75.52%
Evaxion A/S	N/A	-61.43%	-34.23%

Evaxion A/S has higher revenue and earnings than Cardiff Oncology. Evaxion A/S is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$590K	154.26	-$45.85M	-$0.60	N/A
Evaxion A/S	$7.53M	3.92	-$7.71M	-$1.21	N/A

Cardiff Oncology has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market.

In the previous week, Cardiff Oncology and Cardiff Oncology both had 3 articles in the media. Cardiff Oncology's average media sentiment score of 0.91 beat Evaxion A/S's score of 0.89 indicating that Cardiff Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiff Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 8.8% of Cardiff Oncology shares are owned by company insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cardiff Oncology presently has a consensus price target of $7.50, indicating a potential upside of 541.03%. Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 236.39%. Given Cardiff Oncology's higher probable upside, equities analysts plainly believe Cardiff Oncology is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Evaxion A/S beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks.

How does Evaxion A/S compare to DT Cloud Star Acquisition?

Evaxion A/S (NASDAQ:EVAX) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

11.0% of Evaxion A/S shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 52.9% of DT Cloud Star Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market.

DT Cloud Star Acquisition's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
DT Cloud Star Acquisition	N/A	N/A	N/A

DT Cloud Star Acquisition has lower revenue, but higher earnings than Evaxion A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.92	-$7.71M	-$1.21	N/A
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

Evaxion A/S presently has a consensus target price of $11.00, indicating a potential upside of 236.39%. Given Evaxion A/S's stronger consensus rating and higher probable upside, research analysts plainly believe Evaxion A/S is more favorable than DT Cloud Star Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
DT Cloud Star Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Evaxion A/S had 2 more articles in the media than DT Cloud Star Acquisition. MarketBeat recorded 3 mentions for Evaxion A/S and 1 mentions for DT Cloud Star Acquisition. DT Cloud Star Acquisition's average media sentiment score of 1.04 beat Evaxion A/S's score of 0.89 indicating that DT Cloud Star Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Evaxion A/S	Positive
DT Cloud Star Acquisition	Positive

Summary

Evaxion A/S beats DT Cloud Star Acquisition on 7 of the 11 factors compared between the two stocks.

How does Evaxion A/S compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Evaxion A/S had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 3 mentions for Evaxion A/S and 0 mentions for Aadi Bioscience. Evaxion A/S's average media sentiment score of 0.89 beat Aadi Bioscience's score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Evaxion A/S	Positive

Evaxion A/S has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Evaxion A/S's return on equity of -61.43% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Evaxion A/S	N/A	-61.43%	-34.23%

Evaxion A/S has lower revenue, but higher earnings than Aadi Bioscience. Evaxion A/S is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.70	-$65.76M	-$2.35	N/A
Evaxion A/S	$7.53M	3.92	-$7.71M	-$1.21	N/A

52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by company insiders. Comparatively, 41.6% of Evaxion A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Evaxion A/S has a consensus target price of $11.00, suggesting a potential upside of 236.39%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts plainly believe Evaxion A/S is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Aadi Bioscience has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Summary

Evaxion A/S beats Aadi Bioscience on 12 of the 16 factors compared between the two stocks.

How does Evaxion A/S compare to Oncolytics Biotech?

Oncolytics Biotech (NASDAQ:ONCY) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

In the previous week, Oncolytics Biotech had 4 more articles in the media than Evaxion A/S. MarketBeat recorded 7 mentions for Oncolytics Biotech and 3 mentions for Evaxion A/S. Evaxion A/S's average media sentiment score of 0.89 beat Oncolytics Biotech's score of 0.54 indicating that Evaxion A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncolytics Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

6.8% of Oncolytics Biotech shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 0.1% of Oncolytics Biotech shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Evaxion A/S has higher revenue and earnings than Oncolytics Biotech. Evaxion A/S is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncolytics Biotech	N/A	N/A	-$28.76M	-$0.34	N/A
Evaxion A/S	$7.53M	3.92	-$7.71M	-$1.21	N/A

Oncolytics Biotech has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Oncolytics Biotech presently has a consensus price target of $5.00, suggesting a potential upside of 641.29%. Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 236.39%. Given Oncolytics Biotech's higher possible upside, equities analysts clearly believe Oncolytics Biotech is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncolytics Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evaxion A/S's return on equity of -61.43% beat Oncolytics Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncolytics Biotech	N/A	-2,185.97%	-442.99%
Evaxion A/S	N/A	-61.43%	-34.23%

Summary

Evaxion A/S beats Oncolytics Biotech on 8 of the 14 factors compared between the two stocks.

How does Evaxion A/S compare to Citius Oncology?

Evaxion A/S (NASDAQ:EVAX) and Citius Oncology (NASDAQ:CTOR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Evaxion A/S has higher revenue and earnings than Citius Oncology. Evaxion A/S is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	3.92	-$7.71M	-$1.21	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

In the previous week, Evaxion A/S and Evaxion A/S both had 3 articles in the media. Citius Oncology's average media sentiment score of 1.23 beat Evaxion A/S's score of 0.89 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Citius Oncology	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.52, suggesting that its share price is 252% more volatile than the broader market.

Evaxion A/S presently has a consensus price target of $11.00, suggesting a potential upside of 236.39%. Given Evaxion A/S's stronger consensus rating and higher possible upside, research analysts plainly believe Evaxion A/S is more favorable than Citius Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evaxion A/S's return on equity of -61.43% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-34.23%
Citius Oncology	N/A	-102.98%	-43.49%

Summary

Evaxion A/S beats Citius Oncology on 8 of the 13 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVAX vs. The Competition

Export

Metric	Evaxion A/S	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$29.23M	$3.96B	$7.34B	$13.05B
Dividend Yield	N/A	3.63%	2.52%	14.18%
P/E Ratio	-2.70	13.66	273.79	25.68
Price / Sales	3.92	1,346.82	626.32	85.12
Price / Cash	N/A	121.91	80.06	52.35
Price / Book	1.60	15.28	10.44	6.34
Net Income	-$7.71M	-$22.71M	$3.50B	$360.56M
7 Day Performance	-0.91%	-2.05%	-1.41%	-1.59%
1 Month Performance	8.64%	-8.36%	-4.17%	-4.08%
1 Year Performance	-13.03%	26.25%	12.60%	3.79%

Evaxion A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVAX Evaxion A/S	2.6905 of 5 stars	$3.27 +0.9%	$11.00 +236.4%	-13.9%	$29.23M	$7.53M	N/A	46	News Coverage
CRDF Cardiff Oncology	2.1615 of 5 stars	$1.33 -2.9%	$7.50 +463.9%	-43.8%	$106.58M	$590K	N/A	31
DTSQ DT Cloud Star Acquisition	1.339 of 5 stars	$11.60 +0.9%	N/A	+10.6%	$102.36M	N/A	N/A	3	Positive News
AADI Aadi Bioscience	N/A	$4.04 -3.8%	N/A	+93.8%	$99.78M	$25.07M	N/A	40
ONCY Oncolytics Biotech	2.2348 of 5 stars	$0.71 -6.9%	$5.00 +601.0%	-52.2%	$97.71M	N/A	N/A	29	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVAX) was last updated on 9/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evaxion A/S (EVAX) Competitors

EVAX vs. CRDF, DTSQ, AADI, ONCY, and CTOR

How does Evaxion A/S compare to Cardiff Oncology?

Summary

How does Evaxion A/S compare to DT Cloud Star Acquisition?

Summary

How does Evaxion A/S compare to Aadi Bioscience?

Summary

How does Evaxion A/S compare to Oncolytics Biotech?

Summary

How does Evaxion A/S compare to Citius Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evaxion A/S (EVAX) Competitors

EVAX vs. CRDF, DTSQ, AADI, ONCY, and CTOR

How does Evaxion A/S compare to Cardiff Oncology?

Is CRDF or EVAX more profitable?

Which has higher valuation & earnings, CRDF or EVAX?

Which has more risk and volatility, CRDF or EVAX?

Does the media favor CRDF or EVAX?

Do insiders & institutionals believe in CRDF or EVAX?

Do analysts recommend CRDF or EVAX?

Summary

How does Evaxion A/S compare to DT Cloud Star Acquisition?

Do institutionals and insiders believe in EVAX or DTSQ?

Which has more risk and volatility, EVAX or DTSQ?

Is EVAX or DTSQ more profitable?

Which has better valuation & earnings, EVAX or DTSQ?

Do analysts prefer EVAX or DTSQ?

Does the media favor EVAX or DTSQ?

Summary

How does Evaxion A/S compare to Aadi Bioscience?

Does the media prefer AADI or EVAX?

Is AADI or EVAX more profitable?

Which has stronger valuation & earnings, AADI or EVAX?

Do institutionals & insiders believe in AADI or EVAX?

Do analysts prefer AADI or EVAX?

Which has more risk & volatility, AADI or EVAX?

Summary

How does Evaxion A/S compare to Oncolytics Biotech?

Does the media prefer ONCY or EVAX?

Do institutionals & insiders hold more shares of ONCY or EVAX?

Which has better valuation & earnings, ONCY or EVAX?

Which has more volatility & risk, ONCY or EVAX?

Do analysts recommend ONCY or EVAX?

Is ONCY or EVAX more profitable?

Summary

How does Evaxion A/S compare to Citius Oncology?

Do institutionals and insiders have more ownership in EVAX or CTOR?

Which has stronger valuation and earnings, EVAX or CTOR?

Does the media refer more to EVAX or CTOR?

Which has more volatility & risk, EVAX or CTOR?

Do analysts rate EVAX or CTOR?

Is EVAX or CTOR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools